Moderna COVID-19 vaccine: Less breakthrough infections than Pfizer’s
- Novavax COVID-19 vaccine gets emergency use authorization in US
- FDA Fast Track Designation = Immediate Surge in Stock Prices?
- France Resumes COVID-19 Vaccination Campaign
- Why did Early American Settlers stuggling with “Prairie Madness”?
- Largest Healthcare Group in the US Initiates Strike
- Targeting Sugar Molecules in Sugar-Immune Therapy
Moderna COVID-19 vaccine: Less breakthrough infections than Pfizer’s
- Cardiovascular Diseases Linked to COVID-19 Infections
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
Moderna COVID-19 vaccine: Less breakthrough infections than Pfizer’s.
Moderna’s COVID-19 mRNA vaccine leads to less breakthrough infections and hospitalizations than Pfizer’s.
At the end of 2020, it took only one year for Pfizer/BioNTech and Moderna to develop a COVID-19 mRNA vaccine , which was approved for marketing.
This also allows the world to see the great potential of mRNA vaccines.
With the continuous emergence and large-scale spread of new mutants of the new coronavirus, the protective effect of the vaccines developed against the original strains began to decline, and some people who had received two doses of mRNA vaccines were still infected with the new coronavirus, which is the so-called ” breakthrough “. infection “.
On January 20, 2022, researchers from Case Western Reserve University and others published a paper on JAMA, entitled: Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period.
The paper compared breakthrough infections, hospitalizations, and deaths during the delta mutant epidemic between two mRNA vaccines from Pfizer/BioNTech and Moderna , respectively.
The results showed that people who received the Moderna vaccine had a lower risk of breakthrough infection and hospitalization compared with the Pfizer/BioNTech mRNA vaccine .
Rong Xu , who led the study, is a professor of bioinformatics at Case Western Reserve University School of Medicine and director of the Center for Artificial Intelligence Drug Discovery.
He led a team that analyzed electronic health records of more than 637,000 fully vaccinated patients from 63 U.S. health care facilities, covering different regions, ages, races and ethnicities, income levels and insurance status.
The research team compared breakthrough infections, hospitalizations, and mortality associated with the delta mutant in recipients of the Moderna mRNA vaccine and the Pfizer/BioNTech mRNA vaccine, taking into account recipient characteristics and different times after vaccination.
The statistics are based on a breakthrough infection of the COVID-19 between July 2021 and November 2021, when Delta accounted for almost all cases.
The team considered demographics, social determinants of health, transplantation and comorbidities. Hospitalization rates of patients within 60 days of infection were also compared.
Statistical results show that compared with Pfizer/BioNTech’s mRNA vaccine, the monthly breakthrough infection rate of people vaccinated with Moderna’s mRNA is lower .
The population vaccinated with Pfizer/BioNTech’s mRNA vaccine was 2.8‰ .
The hospitalization rate within 60 days of vaccination was 12.7% for those who received Moderna’s mRNA, compared to 13.3% for those who received the Pfizer/BioNTech mRNA vaccine. But there was no significant difference in mortality among those who received the two mRNA vaccines.
These data suggest that the two mRNA vaccines, despite their differences in preventing breakthrough infections, both have good protection against severe disease.
With the rapid spread of Omicron, it is necessary to further evaluate the protective effect of the booster needle, and it is also necessary to develop a vaccine against Omicron.
Paper link :
https://jamanetwork.com/journals/jama/fullarticle/2788408
Moderna COVID-19 vaccine: Less breakthrough infections than Pfizer’s
(source:internet, reference only)
Disclaimer of medicaltrend.org
